Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Activation of the ERK pathway is a hallmark of cancer, and targeting of upstream signaling partners led to the development of approved drugs. Recently, SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor. Here we report the structural mechanism for its remarkable selectivity. In ERK1/2, SCH772984 induces a so-far-unknown binding pocket that accommodates the piperazine-phenyl-pyrimidine decoration. This new binding pocket was created by an inactive conformation of the phosphate-binding loop and an outward tilt of helix αC. In contrast, structure determination of SCH772984 with the off-target haspin and JNK1 revealed two canonical but distinct type I binding modes. Notably, the new binding mode with ERK1/2 was associated with slow binding kinetics in vitro as well as in cell-based assay systems. The described binding mode of SCH772984 with ERK1/2 enables the design of a new type of specific kinase inhibitors with prolonged on-target activity.

Original publication

DOI

10.1038/nchembio.1629

Type

Journal article

Journal

Nat Chem Biol

Publication Date

10/2014

Volume

10

Pages

853 - 860

Keywords

Antineoplastic Agents, Binding Sites, Cell Line, Tumor, Enzyme Inhibitors, Gene Expression, Gene Expression Regulation, Neoplastic, Humans, Indazoles, Intracellular Signaling Peptides and Proteins, Kinetics, MAP Kinase Signaling System, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Mitogen-Activated Protein Kinase 8, Piperazines, Protein Binding, Protein Structure, Secondary, Protein Structure, Tertiary, Protein-Serine-Threonine Kinases, Recombinant Proteins